logo
Plus   Neg
Share
Email

Novartis: CAN-COVID Trial Fails To Meet Its Primary Endpoint - Quick Facts

Novartis (NVS) reported that new data from an interim analysis for the placebo-controlled CAN-COVID trial evaluating canakinumab in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome. The company said the trial failed to meet its primary endpoint showing that treatment with canakinumab plus standard of care did not show a significantly greater chance of survival for patients without the need for invasive mechanical ventilation, compared with placebo plus SoC up to Day 291.

The trial did not meet its key secondary endpoint of reducing the COVID-19-related death rate during the 4-week period after treatment.

Novartis noted that a phase III trial for ruxolitinib in COVID-19 is ongoing, with preliminary results expected by year end.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
House-Autry Mills, Inc. issued a recall for its 9 ounce bottles of House-Autry Tartar Sauce due to the co-manufacturer's verification of spoilage associated with the product, according to a statement published by the U.S. Food and Drug Administration or FDA. The North Carolina-based company said the product may be unsuitable for consumption. Kimberly-Clark Corp. (KMB) on Monday reported a profit for the fourth quarter that edged down from last year, hurt by higher expenses, despite 6 percent sales growth. Both adjusted earnings per share and net sales topped analysts' expectations. The company also initiated adjusted earnings and net sales growth guidance for the full-year 2021. Shares of Philips Electronics NV were gaining around 3 percent in Amsterdam trading after the Dutch consumer electronics giant reported Monday higher results in its fourth quarter. The company also proposed dividend, and said it sees growth in fiscal 2021 comparable sales and adjusted margin.
Follow RTT